Cuộc họp báo cáo kết quả kinh doanh Quý 3/2026 của AtriCure (ATRC): Doanh thu tăng 15%, Nâng triển vọng EBITDA
Doanh thu quý 3/2026 của AtriCure tăng 15% lên 154,5 triệu USD nhờ mảng triệt đốt và quản lý đau tại Mỹ tăng trưởng. Ban lãnh đạo đã nâng dự báo EBITDA điều chỉnh.
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.